Amarin | AMRN - Ebitda





Ebitda تغيير تاريخ
AbbVie USD 5.37B 1.85B 2025-12
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amarin USD 12.54M 28.57M 2025-06
AstraZeneca USD 5.67B 1.29B 2026-03
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
DBV Technologies USD -45.9M 12.42M 2026-03
GlaxoSmithKline GBP 3.51B 734M 2026-06
Halozyme Therapeutics USD 219.57M 197.66M 2026-03
Heron Therapeutics USD -3.88M 5.63M 2024-09
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 6.48B 1.19B 2026-06